Comprehensive mapping of immune perturbations associated with severe COVID-19
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
Profound plasmablast expansion, innate cell modulation, and T cell activation are defining features of severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We believe that the features described herein may help to identify the immunopathology of similar illnesses, such as irAEs and CRS due to other immunotherapies (e.g. checkpoint inhibitors, CAR-T-cells) or COVID-19 [4, 18, 19], and to inform discussions on the type and length of clinical and immune monitoring warranted in such patients.”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical–pathologic correlation in these individuals resulted in valuable observations that may be instructive in understanding mechanisms of immune-induced pathologies, including those of checkpoint inhibitors, CAR-T cells, and infections such as COVID-19, known to target mucosal tissues and cause severe CRS [1, 5, 8, 18, 19].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting the lung as a source for the elevated plasma levels of type I IFNs early on infection”
From COVID-19 and the human innate immune system (2021) · cites this paper as Kuri-Cervantes et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ineffective IFN innate immunity has been strongly associated with failure to control a primary SARS-CoV-2 infection and a high risk of fatal COVID-19, accompanied by innate cell immunopathology and a plasma cytokine signature of elevated CXCL10, interleukin (IL)-6, and IL-8 in many studies (Aid et al., 2020; Kuri-Cervantes et al., 2020; Li et al., 2020b; Lucas et al., 2020; Radermecker et al., 202”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Kuri-Cervantes et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“particularly observation of elevated frequencies of neutrophils (the most common cell type of the innate immune system) in blood (Kuri-Cervantes et al., 2020), and massive numbers of neutrophils in lungs, associated with severe, end-stage COVID-19 disease (Li et al., 2020b; Liao et al., 2020; Radermecker et al., 2020; Schurink et al., 2020). In contrast, end-stage disease is not generally”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Kuri-Cervantes et al., 2020
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0498-4 · Cited by 175
RetractedWang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0424-9 · Cited by 161
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Martínez–González, M. B. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,296
Binary Codes capable of currecting deletions, insertions, and reversals
Levenshtein, V. I. (1965) · Soviet physics. Doklady · Cited by 14,807
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Research works printed but not linked: 2
- WHO Novel Coronavirus 2019 Reports (World Health Organization 2020) vol. 2020.
- 10.1146/annurev.iy.13.040195.001015 · doi:10.1146/annurev.iy.13.040195.001015 · Paper page
Cited by
Items 501–600 of 761
T helper cell subsets and related target cells in acute COVID-19
Kudryavtsev, I. V., Головкин, А. С., & Тотолян, А. А. (2022) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-thc-1882 · Cited by 8
Distorted TCR repertoires define multisystem inflammatory syndrome in children
Malik, A., Tóth, E. N., Teng, M. S., Hurst, J. M., Watt, E., Wise, L., Kent, N., Bartram, J. L., Grandjean, L., Dominguez‐Villar, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274289 · Cited by 8
Tuberculosis and COVID-19 in the elderly: factors driving a higher burden of disease
Allué‐Guardia, A., Torrelles, J. B., & Sigal, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1250198 · Cited by 11
Hanson, A., Cohen, H. B., Wang, H., Shekhar, N., Shah, C., Dhaneshwar, A., Harvey, B. W., Murray, R., & Harvey, C. J. (2020) · medRxiv · doi:10.1101/2020.12.16.20248343 · Cited by 8
Cholinergic and lipid mediators crosstalk in Covid-19 and the impact of glucocorticoid therapyPreprint
Pérez, M. M., Pimentel, V. E., Fuzo, C. A., Silva-Neto, P. V. D., Toro, D. M., Souza, C. O. S., Fraga‐Silva, T. F. D. C., Gardinassi, L. G., de Carvalho, J. C. S., Neto, N. T., et al. (2021) · medRxiv · doi:10.1101/2021.01.07.20248970 · Cited by 8
Chimeric Construct Engineering with Human Variant HLA-A*02:01:01:01
Karkischenko, V. N., Petrova, N. V., Савченко, Е. С., Сергеевна, О. Н., Колоскова, Е. М., Максименко, С. В., Manuvera, V. A., Bobrovsky, P. A., & Лазарев, В. Н. (2021) · Journal Biomed · doi:10.33647/2074-5982-17-1-10-23 · Cited by 7
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets
Hachim, A., Kavian, N., & Valkenburg, S. A. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.08.006 · Cited by 7
Banerjee, U., Chunchanur, S. K., Ambica, R., Balaji, K. N., Singh, A., Chakravortty, D., & Chandra, N. R. (2023) · Genes and Immunity · doi:10.1038/s41435-023-00210-1 · Cited by 7
Modeling “Two-Hit” Severe Pneumonia in Mice: Pathological Characteristics and Mechanistic Studies
Zhao, M., Wang, B., Zhou, F., Fang, C., Zhu, B., Zhou, M., Ye, X., Chen, Y., & Ding, Z. (2024) · Inflammation · doi:10.1007/s10753-024-02136-w · Cited by 7
Immunomics in one health: understanding the human, animal, and environmental aspects of COVID-19
Gao, J., Zhang, C., Wheelock, Å. M., Xin, S., Cai, H., Xu, L., & Wang, X.-J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450380 · Cited by 7
Zhao, M., Liu, Z., Shao, F., Zhou, W., Zhu, C., Xia, P., Wang, S., & Yang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729990 · Cited by 7
Gupta, M., Balachandran, H., Louie, R. H. Y., Li, H., Agapiou, D., Keoshkerian, E., Christ, D., Rawlinson, W. D., Mina, M., Post, J. J., et al. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12607 · Cited by 7
Identification of natural killer markers associated with fatal outcome in COVID-19 patients
Tarantino, N., Litvinova, E., Samri, A., Soulié, C., Morin, V., Rousseau, A., Dorgham, K., Parizot, C., Bonduelle, O., Beurton, A., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1165756 · Cited by 7
Ren, J.-X., Gao, Q., Zhou, X.-C., Chen, L., Guo, W., Feng, K., Lü, L., Huang, T., & Cai, Y. (2023) · Biology · doi:10.3390/biology12070947 · Cited by 7
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
Carlini, F., Lusi, V., Rizzi, C., Assogna, F., & Laroni, A. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00520-6 · Cited by 7
Xing, Y., Li, Y., Feng, L., Huo, R., Ma, X., Dong, Y., Liu, D., Niu, Y., Tian, X., & Chen, E. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s418622 · Cited by 8
Pathogenesis of Pulmonary Long COVID-19
Borczuk, A. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100378 · Cited by 10
The Prognostic Utility of Cytokines in Hospitalized COVID-19 Patients
Andrejkovits, Á. V., Huţanu, A., Susányi, E. J., Negrea, V., & Văsieșiu, A.-M. (2023) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2023-0025 · Cited by 8
IL-18 Responsiveness Defines Limitations in Immune Help for Specialized FcRγ– NK Cells
Anderko, R. R., Rinaldo, C. R., & Mailliard, R. B. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000430 · Cited by 8
AIRRscape: An interactive tool for exploring B-cell receptor repertoires and antibody responses
Waltari, E., Nafees, S., Wong, J., McCutcheon, K. M., & Pak, J. E. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010052 · Cited by 8
Damato, V., Spagni, G., Monte, G., Scandiffio, L., Cavalcante, P., Zampetti, N., Fossati, M., Falso, S., Mantegazza, R., Battaglia, A., et al. (2023) · Neuromuscular Disorders · doi:10.1016/j.nmd.2023.02.005 · Cited by 8
Multi-omic profiling reveals early immunological indicators for identifying COVID-19 Progressors
Drake, K., Talantov, D., Tong, G. J., Lin, J. T., Verheijden, S., Katz, S., Leung, J. M., Yuen, B., Krishna, V., Wu, M. J., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109808 · Cited by 9
Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center
Agostinis, P., Vianello, V., Dereani, E., Caruso, G., Montessoro, B., Taurian, M., Chiara, A. D., Patruno, V., Cavallin, F., Fadini, G. P., et al. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01784-w · Cited by 7
Cellular Immune Profiling of Lung and Blood Compartments in Patients with SARS-CoV-2 Infection
Santinelli, L., Lazzaro, A., Sciarra, F., Maddaloni, L., Frasca, F., Fracella, M., Moretti, S., Borsetti, A., Bugani, G., Alessandri, F., et al. (2023) · Pathogens · doi:10.3390/pathogens12030442 · Cited by 7
Bayındır, M., & Bayindir, E. E. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3648292 · Cited by 7
Sheerin, D., Phan, T. K., Eriksson, E. M., & Coussens, A. K. (2023) · medRxiv · doi:10.1101/2023.05.24.23290499 · Cited by 9
Meira, D. D., Zetum, A. S. S., Casotti, M. C., da Silva, D. R. C., de Araújo, B. C., Vicente, C. R., Duque, D. D. A., Campanharo, B. P., Garcia, F. M., Campanharo, C. V., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34393 · Cited by 8
Lisowska, K. A., Ciesielska-Figlon, K., Komorniczak, M., Bułło‐Piontecka, B., Dębska-Ślizień, A. M., & Wardowska, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158278 · Cited by 6
A detailed examination of coronavirus disease 2019 (COVID-19): Covering past and future perspectives
Yasmin, S., & Ansari, M. Y. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107398 · Cited by 6
Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
Wei, X., Rong, N., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993754 · Cited by 6
Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization
Bertoletti, A., Bert, N. L., & Tan, A. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810679 · Cited by 6
Maurya, D. K., Sharma, D., & Sandur, S. K. (2023) · Free Radical Research · doi:10.1080/10715762.2023.2178918 · Cited by 6
Ulakcsai, Z., Szabó, L. E., Szabo, Z., Karászi, É., Szabó, T. G., Fazekas, L., Vereb, A., Kovacs, N. F., Németh, D., Kovács, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1179620 · Cited by 7
Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations
Starshinova, A. A., Borozinets, A. A., Kulpina, A., Sereda, V., Rubinstein, A., Kudryavtsev, I. V., & Kudlay, D. A. (2024) · Pathophysiology · doi:10.3390/pathophysiology31020020 · Cited by 8
Andrievskaya, I. A., Лязгиян, К. С., Жуковец, И. В., & Михайлович, У. Е. (2024) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2024-2-5-13 · Cited by 6
COVID ‐19: Using high‐throughput flow cytometry to dissect clinical heterogeneity
del Barrio, I. D. M., Hayday, T. S., Laing, A. G., Hayday, A., & Rosa, F. D. (2021) · Cytometry Part A · doi:10.1002/cyto.a.24516 · Cited by 7
Ljunggren, H., Ask, E. H., Cornillet, M., Strunz, B., Chen, P., Muvva, J. R., Akber, M., Buggert, M., Chambers, B. J., Cuapio, A., et al. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13195 · Cited by 6
Clavarino, G., Leroy, C., Épaulard, O., Raskovalova, T., Vilotitch, A., Pernollet, M., Dumestre‐Pérard, C., Defendi, F., Maréchal, M. L., Gouëllec, A. L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889813 · Cited by 6
Proteomics research of SARS-CoV-2 and COVID-19 disease
Zhang, N., Wang, S., & Wong, C. C. L. (2022) · Medical Review · doi:10.1515/mr-2022-0016 · Cited by 8
HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review
El‐Baky, N. A., Amara, A. A. A. F., & Redwan, E. M. M. M. (2023) · Vaccines · doi:10.3390/vaccines11030548 · Cited by 7
Patients’ Perspectives on Life and Recovery 1 Year After COVID-19 Hospitalization
Chow, C., Chesley, C. F., Ward, M., Neergaard, R., Prasad, T. V., Dress, E. M., Reagan, S., Kalyani, P., Smyk, N. J., Turner, A. P., et al. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08246-9 · Cited by 6
Self-citationIt’s in the blood: a review of the hematological system in SARS-CoV-2-associated COVID-19
Harte, J. V., Coleman-Vaughan, C., Crowley, M. P., & Mykytiv, V. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2232010 · Cited by 7
Genetic signature detected in T cell receptors from patients with severe COVID-19
Corpas, M., de Mendoza, C., Moreno‐Torres, V., Pintos-Pascual, I., Seoane, P., Perkins, J. R., Ranea, J. A. G., Fatumo, S., Korcsmáros, T., Martín‐Villa, J. M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107735 · Cited by 9
Pinski, A. N., Steffen, T. L., Zulu, M. Z., George, S. L., Dickson, A., Tifrea, D., Maroney, K. J., Tedeschi, N., Zhang, Y., Scheuermann, R. H., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4cova0121-084rr · Cited by 7
Neuman, H., Arrouasse, J., Kedmi, M., Cerutti, A., Magri, G., & Mehr, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822834 · Cited by 6
Zhu, J., Chen, T., Mao, X., Fang, Y., Sun, H., Wei, D., & Ji, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.974343 · Cited by 6
Sánchez‐Montalvá, A., Álvarez‐Sierra, D., Martínez‐Gallo, M., Perurena-Prieto, J., Arrese-Muñoz, I., Ruiz‐Rodríguez, J. C., Pereiro, J. E., Bosch‐Nicolau, P., Martínez‐Gómez, X., Antón, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.902837 · Cited by 5
Essa, S. S., Shamsah, M., Alsarraf, A. H., Esmaeil, A., Al-Shammasi, A., & Raghupathy, R. (2022) · Microorganisms · doi:10.3390/microorganisms10112194 · Cited by 5
Jergović, M., Watanabe, M., Bhat, R., Coplen, C. P., Sonar, S. A., Wong, R., Castaneda, Y., Davidson, L., Kala, M., Wilson, R. C., et al. (2023) · GeroScience · doi:10.1007/s11357-022-00724-y · Cited by 6
Li, D., Xu, M., Hooper, A. T., Rofail, D., Mohammadi, K. A., Chen, Y., Ali, S., Norton, T. D., Weinreich, D. M., Musser, B. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39681-7 · Cited by 6
Yang, M. X., Meng, Y., Hao, W., Zhang, J., Liu, J., Wu, L., Lin, B., Liu, Y., Zhang, Y., Yu, X., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111829 · Cited by 5
SARS-CoV-2 and UPS with potentials for therapeutic interventions
Ferdoush, J., Kadir, R. A., Kaplanoğlu, S., & Osborn, M. (2024) · Gene · doi:10.1016/j.gene.2024.148377 · Cited by 5
Berger, L., Wolf, J., Kalbitz, S., Kellner, N., Lübbert, C., & Borte, S. (2024) · Diagnostics · doi:10.3390/diagnostics14121286 · Cited by 5
Günter, M., Mueller, K. A. L., Salazar, M. J., Gekeler, S., Prang, C., Harm, T., Gawaz, M., & Autenrieth, S. E. (2024) · European Journal of Immunology · doi:10.1002/eji.202451145 · Cited by 5
Emerging nanomaterials applied for tackling the COVID-19 cytokine storm
Yang, X., You, J., Wei, Y., Li, H., Gao, L., Guo, Q., Huang, Y., Gong, C., & Cheng, Y. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01446c · Cited by 5
Alterations in the CD56− and CD56+ T Cell Subsets during COVID-19
Vavilova, J. D., Ustiuzhanina, M. O., Boyko, A. A., Streltsova, M. A., Kust, S. A., Kanevskiy, L. M., Iskhakov, R. N., Sapozhnikov, A. M., Gubernatorova, E. O., Drutskaya, M. S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109047 · Cited by 6
Anchor Clustering for million-scale immune repertoire sequencing data
Chang, H., Ashlock, D., Graether, S. P., & Keller, S. M. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05659-z · Cited by 6
Role of Ferroptosis in the Progression of COVID-19 and the Development of Long COVID
Wen, Z., Wang, S., Han, Y., Zhang, H., Cao, J., Dong, S., Li, D., Lei, M., Gao, Y., & Liu, C. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673281662231208102354 · Cited by 5
Silva‐Filho, J. L., Herder, V., Gibbins, M. P., Santana, M. F., de Melo, G. C., Haley, M., Judice, C. C., Val, F., Borba, M. G. S., Tavella, T. A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk9149 · Cited by 5
Meyer, N. J., Lindell, R. B., & Wherry, E. J. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.5536 · Cited by 6
Self-citationRelational interaction between T-lymphocytes and SARS-CoV-2: A review
Chaple, A. R., Vispute, M. M., Mahajan, S., Mushtaq, S., Muthuchelvan, D., Ramakrishnan, M. A., & Sharma, G. K. (2021) · Acta Virologica · doi:10.4149/av_2021_202 · Cited by 5
Adıgüzel, Y. (2021) · Acta Tropica · doi:10.1016/j.actatropica.2021.106013 · Cited by 5
Rives, B. T., Rosales, Y. Z., Valdés, M. M., Balbuena, H. R., Téllez, G. M., Pérez, J. R., Padrón, L. C. M., Pelier, C. V. R., Lugo, F. S., Valdés-Zayas, A., et al. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152216 · Cited by 7
Wang, Z., Zhang, Y., Yang, R., Wang, Y., Guo, J., Sun, R., Zhou, Y. M., Li, S., Ge, Q., & Feng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.831194 · Cited by 5
Solimando, A. G., Bittrich, M., Shahini, E., Albanese, F., Fritz, G., & Krebs, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108746 · Cited by 5
Maiorca, F., Lombardi, L., Marrapodi, R., Pallucci, D., Sabetta, A., Zingaropoli, M. A., Perri, V., Flego, D., Romiti, G. F., Corica, B., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102262 · Cited by 5
Therapeutics for COVID-19: established and in development
Singh, K. P., Sasadeusz, J. J., Lewin, S. R., & Audsley, J. (2020) · Microbiology Australia · doi:10.1071/ma20058 · Cited by 4
Wang, S., Zhao, N., Luo, T., Kou, S., Sun, M., & Chen, K. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01299-y · Cited by 5
Celluloepidemiology—A paradigm for quantifying infectious disease dynamics on a population level
Ha, M. K., Postovskaya, A., Kuznetsova, M. S., Meysman, P., Deuren, V. M. L. V., van Ierssel, S. H., Reu, H. D., Schippers, J., Peeters, K., Besbassi, H., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt2926 · Cited by 4
Tufan, A., & Matucci‐Cerinic, M. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2110-179 · Cited by 4
McCulloch, L. J., Mouat, I. C., South, K., McColl, B. W., Allan, S. M., & Smith, C. J. (2022) · Discovery Immunology · doi:10.1093/discim/kyac004 · Cited by 4
Pascal, V., Dupont, M., de Rouault, P., Rizzo, D., Delphine Rossille, A., Jeannet, R., Daix, T., François, B., Genebrier, S., Cornic, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106260 · Cited by 4
Kandula, U. R., & Wake, A. D. (2023) · Biologics · doi:10.2147/btt.s404421 · Cited by 5
Nemani, K., Picker, L. D., Dickerson, F., Leboyer, M., Santacatterina, M., Ando, F., Capichioni, G., Smith, T. E., Kammer, J., Abdellati, K. E., et al. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100802 · Cited by 6
T-cell immunobiology and cytokine storm of COVID-19
Eltayeb, A., & Redwan, E. M. M. M. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.10.003 · Cited by 4
Reaktionsmuster der lokoregionären Lymphknoten im Abflussgebiet von COVID-19-Lungen
Haslbauer, J. D., Matter, M. S., Stalder, A. K., & Tzankov, A. (2021) · Der Pathologe · doi:10.1007/s00292-021-00914-z · Cited by 4
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy
Sun, L., Surya, S., Goodman, N. G., Le, A. N., Kelly, G., Owoyemi, O., Desai, H., Zheng, C., DeLuca, S., Good, M. L., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00113 · Cited by 4
Self-citationDistinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19
Müller, M. K., Volzke, J., Subin, B., Schmidt, C. J., Geerdes-Fenge, H. F., Reisinger, E. C., & Müller‐Hilke, B. (2022) · Viruses · doi:10.3390/v14020203 · Cited by 4
Sengupta, S., Bhattacharya, G., Chatterjee, S., Datey, A., Shaw, S. K., Suranjika, S., Nath, P., Barik, P. K., Prasad, P., Chattopadhyay, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848335 · Cited by 4
The Relationship between Immature Granulocyte Count and Mortality in Ards Due to Covid-19
Alay, G. H., Tatlisuluoglu, D., Bulut, K., Fikri, B. İ., Öztaş, A., & Turan, G. (2022) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_118_22 · Cited by 4
Nawaz, M., Ashraf, M. A., Ali, M. A., Shabbir, M. Z., Shabbir, M. A. B., Altaf, I., Raza, S., Rafique, S., Hassan, S., Sardar, N., et al. (2022) · Life · doi:10.3390/life12091424 · Cited by 4
Mapping global trends in research of stem cell therapy for COVID-19: A bibliometric analysis
Zhang, X., Cai, J., Chen, L., Yang, Q., Tian, H., Wu, J., Ji, Z., Zheng, D., Li, Z., & Chen, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1016237 · Cited by 4
Shared 6mer Peptides of Human and Omicron (21K and 21L) at SARS-CoV-2 Mutation Sites
Adıgüzel, Y., & Shoenfeld, Y. (2022) · Antibodies · doi:10.3390/antib11040068 · Cited by 4
Ahmed, N., Athavale, A., Tripathi, A. H., Subramaniam, A., Upadhyay, S. K., Pandey, A. K., Rai, R. C., & Awasthi, A. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13345 · Cited by 4
Longitudinal analyses reveal age-specific immune correlates of COVID-19 severityPreprint
Lewis, S. A., Sureshchandra, S., Zulu, M. Z., Doratt, B. M., Pinski, A. N., Curtis, M., Jankeel, A., Ibraim, I. C., Rhoades, N. S., Jiang, X., et al. (2021) · medRxiv · doi:10.1101/2021.01.25.21250189 · Cited by 4
Coronavirus antibody screening identifies children with mild to moderate courses of PMISPreprint
Laub, O., Leipold, G., Toncheva, A. A., Peterhoff, D., Einhauser, S., Borchers, N. S., Santos-Valente, E., Kheiroddin, P., Buntrock‐Döpke, H., Laub, S., et al. (2020) · doi:10.22541/au.160776187.78854537/v1 · Cited by 5
COVID-19 immune signatures in Uganda persist in HIV co-infection and diverge by pandemic phase
Cummings, M. J., Bakamutumaho, B., Lutwama, J. J., Owor, N., Che, X., Astorkia, M., Postler, T. S., Kayiwa, J. T., Kiconco, J., Muwanga, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45204-3 · Cited by 3
POST-COVID EFFECTS AND IMMUNOLOGICAL MARKERS OF AGING
Kril, I., Chopyak, V. V., Melnykova, N., Bazylevych, A., & Shakhovska, N. (2024) · Proceedings of the Shevchenko Scientific Society Medical Sciences · doi:10.25040/ntsh2024.02.11 · Cited by 3
Gervásio, J. H. D. B., Greenshields‐Watson, A., Quast, N. P., Abanades, B., Felicori, L. F., & Deane, C. M. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169509 · Cited by 3
Leberzammer, J., Abplanalp, W. T., Grikscheit, K., Solomonidis, E. G., Glaser, S.-F., Schuhmacher, B., Merten, M., Jeremijev, G., Wilken‐Schmitz, A., Korth, L., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf268 · Cited by 3
An unconventional view of COVID-19 T cell immunity
Koay, H., Fulford, T. S., & Godfrey, D. I. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201727 · Cited by 3
B-Cell Responses to Sars-Cov-2 mRNA Vaccines
Kardava, L., Buckner, C. M., & Moir, S. L. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.550 · Cited by 3
Sejdic, A., Hartling, H. J., Holler, J. G., Gjærde, L. K., Lindegaard, B., Dungu, A. M., Gnesin, F., Møller, M. E. E., Teglgaard, R. S., Niemann, C. U., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360843 · Cited by 3
Ghosh, S., & Sarma, J. D. (2025) · Biogerontology · doi:10.1007/s10522-025-10252-9 · Cited by 3
Ferreira, H. A. S., Guimarães, L. C., Costa, P. A. C., de Campos, C. L. V., Scalzo, S., Queiroz‐Junior, C. M., Figueiredo, M. M., Teixeira, M. M., Costa, V. V., & Guimarães, P. P. G. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126073 · Cited by 5
A Cytometrist's Guide to Coordinating and Performing Effective COVID ‐19 Research
Chattopadhyay, P. K., Filby, A. J., Jellison, E. R., Ferrari, G., Green, C., Cherian, S., Irish, J. M., Litwin, V., & other members of the ISAC COVID‐19 Work Group (2020) · Cytometry Part A · doi:10.1002/cyto.a.24210 · Cited by 3
Coutant, F., Pin, J., Morfin, F., Ferry, T., Paul, S., Pozzetto, B., Normand, M., & Miossec, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011095 · Cited by 3
Zalewska−Ziob, M., Fus, W., Konka, A., Wystyrk, K., Bochenek, A., Botor, H., Fronczek, M., Zembala-John, J., & Adamek, B. (2022) · Vaccines · doi:10.3390/vaccines10091546 · Cited by 6
Zhang, W., Clemens, E. B., Kedzierski, Ł., Chua, B. Y. L., Mayo, M. J., Lonzi, C., Hinchcliff, A., Rigas, V., Middleton, B. F., Binks, P., et al. (2023) · Immunology and Cell Biology · doi:10.1111/imcb.12691 · Cited by 3
Systems biology of B cells in COVID-19
Woodruff, M. C., Faliti, C. E., & Sanz, I. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101875 · Cited by 3
Metadata
- Authors
- Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., Kuthuru, O., Apostolidis, S. A., Bershaw, L., Dougherty, J., Greenplate, A. R., Pattekar, A., Kim, J., Han, N., Gouma, S., Weirick, M. E., Arevalo, C. P., Bolton, M. J., Goodwin, E. C., Anderson, E. M., Hensley, S. E., Jones, T. K., Mangalmurti, N. S., Luning Prak, E. T., Wherry, E. J., Meyer, N. J., & Betts, M. R.
- Affiliations
- University of Pennsylvania (US)
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, PA 19104, USA.
- Children's Hospital of Philadelphia (US)
- Hospital of the University of Pennsylvania (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Kuri-Cervantes, Leticia
- Wherry, E. John
- Meyer, Nuala J.
- Betts, Michael R.
- ORCID
- Kuri-Cervantes, Leticia
- Pampena, Maria Betina
- Meng, Wenzhao
- Rosenfeld, Aaron M.
- Weisman, Ariel R.
- Agyekum, Roseline S.
- Mathew, Divij
- Baxter, Amy E.
- Vella, Laura A.
- Kuthuru, Oliva
- Apostolidis, Sokratis A.
- Bershaw, Luanne
- Dougherty, Jeanette
- Greenplate, Allison R.
- Pattekar, Ajinkya
- Kim, Justin
- Han, Nicholas
- Gouma, Sigrid
- Weirick, Madison E.
- Arevalo, Claudia P.
- Bolton, Marcus J.
- Anderson, Elizabeth M.
- Hensley, Scott E.
- Jones, Tiffanie K.
- Mangalmurti, Nilam S.
- Luning Prak, Eline T.
- Wherry, E. John
- Meyer, Nuala J.
- Betts, Michael R.
- Venue
- Science Immunology
- Published
- 2020-07-03
- Volume
- 5
- Issue
- 49
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7402634
- OpenAlex
- W3042587425
- Cited by
- 723
- References
- 107
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 63 · 2023: 101 · 2022: 182 · 2021: 251 · 2020: 83
- FWCI
- 20.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (HL137006, HL137915, AI144288, P30-CA016520, AI105343, AI115712, AI117950, AI108545, AI082630, CA210944, T32 CA009140.)
- National Institute of Allergy and Infectious Diseases (AI136660)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- severe COVID-19, SARS-CoV-2, immune perturbation, hyperinflammation, T cell activation, innate lymphoid cells, granulocytes, neutrophil-to-lymphocyte ratio, prognostic factors, organ failure
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Aged, Female, Humans, Immunity, Innate, Immunologic Memory, Lymphocyte Activation, Male, Middle Aged, Neutrophils, Pneumonia, Viral, T-Lymphocytes, B-Lymphocyte Subsets, Cytokines, Coronavirus Infections, Lymphocyte Count, Pandemics, Clonal Selection, Antigen-Mediated
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.